CoChat
Sign Up
Cited by 518Dermatology and Skin DiseasesAsthma and respiratory diseasesAllergic Rhinitis and Sensitization

Mechanisms of Dupilumab

Open access
Harb, Hani, Chatila, Talal A.·2020·Clinical & Experimental Allergy
DOI 10.1111/cea.13491PMC PMC6930967
Open this paper in CoChat — free account

Abstract

The Th2 cytokines interleukin 4 (IL‐4) and IL‐13 and the heterodimeric IL‐4 receptor (IL‐4R) complexes that they interact with play a key role in the pathogenesis of allergic disorders. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL‐4 receptor alpha chain (IL‐4Rα), common to both IL‐4R complexes: type 1 (IL‐4Rα/γc; IL‐4 specific) and type 2 (IL‐4Rα/IL‐13Rα1; IL‐4 and IL‐13 specific). In this review, we detail the current state of knowledge of the different signalling pathways coupled to the IL‐4R complexes and examine the possible mechanisms of Dupilumab action and survey its clinical efficacy in different allergic disorders. The development of Dupilumab and the widening spectrum of its clinical applications is relevant to the current emphasis on precision medicine approaches to the blockade of pathways involved in allergic diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cea.13491

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 86

  1. [1]Kabesch M Early origins of asthma (and allergy). Mol Cell Pediatr. 2016; 3(1): 31. 27510897 PMC4980323
  2. [2]Hasegawa K, Tsugawa Y, Brown DF, Camargo CA Jr., Childhood asthma hospitalizations in the United States, 2000–2009. J Pediatr. 2013; 163(4): 1127– 1133 e1123. 23769497 PMC3786053
  3. [3]Skolnik NS, Carnahan SP. Primary care of asthma: new options for severe eosinophilic asthma. Curr Med Res Opin. 2019: 1. 30880484
  4. [4]Shamoun L, Skarstedt M, Andersson RE, Wagsater D, Dimberg J. Association study on IL-4, IL-4Ralpha and IL-13 genetic polymorphisms in Swedish patients with colorectal cancer. Clin Chim Acta. 2018; 487: 101– 106. 30227113
  5. [5]Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med. 2004; 10(10): 493– 499. 15464449
  6. [6]Keegan AD, Zamorano J, Keselman A, Heller NM. IL-4 and IL-13 Receptor Signaling From 4PS to Insulin Receptor Substrate 2: There and Back Again, a Historical View. Front Immunol 2018; 9: 1037. 29868002 PMC5962649
  7. [7]Chiaramonte MG, Mentink-Kane M, Jacobson BA, Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med. 2003; 197(6): 687– 701. 12642601 PMC2193852
  8. [8]Howard TD, Koppelman GH, Xu J, Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet. 2002; 70(1): 230– 236. 11709756 PMC384891
  9. [10]Wood N, Whitters MJ, Jacobson BA, Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003; 197(6): 703– 709. 12642602 PMC2193851
  10. [11]Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003; 300(5625): 1527– 1528. 12791978
  11. [12]Ryan JJ, McReynolds LJ, Huang H, Nelms K, Paul WE. Characterization of a mobile Stat6 activation motif in the human IL-4 receptor. J Immunol. 1998; 161(4): 1811– 1821. 9712048
  12. [13]Ma B, Wu Y, Chen B, Cyanidin-3-O-beta-glucoside attenuates allergic airway inflammation by modulating the IL-4Ralpha-STAT6 signaling pathway in a murine asthma model. Int Immunopharmacol. 2019; 69: 1– 10. 30660871
  13. [14]Umeshita-Suyama R, Sugimoto R, Akaiwa M, Characterization of IL-4 and IL-13 signals dependent on the human IL-13 receptor alpha chain 1: redundancy of requirement of tyrosine residue for STAT3 activation. Int Immunol. 2000; 12(11): 1499– 1509. 11058569
  14. [15]Roy B, Bhattacharjee A, Xu B, Ford D, Maizel AL, Cathcart MK. IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats. J Leukoc Biol. 2002; 72(3): 580– 589. 12223527
  15. [16]Keegan AD, Nelms K, White M, Wang LM, Pierce JH, Paul WE. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell. 1994; 76(5): 811– 820. 8124718
  16. [17]Byles V, Covarrubias AJ, Ben-Sahra I, The TSC-mTOR pathway regulates macrophage polarization. Nat Commun. 2013; 4: 2834. 24280772 PMC3876736
  17. [18]Festuccia WT, Pouliot P, Bakan I, Sabatini DM, Laplante M. Myeloid-specific Rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharide. PLoS One. 2014; 9(4): e95432. 24740015 PMC3989321
  18. [19]Hallowell RW, Collins SL, Craig JM, mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis. Nat Commun. 2017; 8: 14208. 28128208 PMC5290163
  19. [20]Pruett W, Yuan Y, Rose E, Batzer AG, Harada N, Skolnik EY. Association between GRB2/Sos and insulin receptor substrate 1 is not sufficient for activation of extracellular signal-regulated kinases by interleukin-4: implications for Ras activation by insulin. Mol Cell Biol. 1995; 15(3): 1778– 1785. 7862167 PMC230402
  20. [21]McCormick SM, Gowda N, Fang JX, Heller NM. Suppressor of Cytokine Signaling (SOCS)1 Regulates Interleukin-4 (IL-4)-activated Insulin Receptor Substrate (IRS)-2 Tyrosine Phosphorylation in Monocytes and Macrophages via the Proteasome. J Biol Chem. 2016; 291(39): 20574– 20587. 27507812 PMC5034051
  21. [22]Huang SC, Smith AM, Everts B, Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation. Immunity. 2016; 45(4): 817– 830. 27760338 PMC5535820
  22. [23]Blaeser F, Bryce PJ, Ho N, Targeted inactivation of the IL-4 receptor alpha chain I4R motif promotes allergic airway inflammation. J Exp Med. 2003; 198(8): 1189– 1200. 14557412 PMC2194235
  23. [24]Dasgupta P, Dorsey NJ, Li J, The adaptor protein insulin receptor substrate 2 inhibits alternative macrophage activation and allergic lung inflammation. Sci Signal. 2016; 9(433): ra63. 27330190 PMC5504879
  24. [25]Tachdjian R, Al Khatib S, Schwinglshackl A, In vivo regulation of the allergic response by the IL-4 receptor alpha chain immunoreceptor tyrosine-based inhibitory motif. J Allergy Clin Immunol. 2010; 125(5): 1128– 1136 e1128. 20392476 PMC2889905
  25. [26]Johnson DJ, Pao LI, Dhanji S, Murakami K, Ohashi PS, Neel BG. Shp1 regulates T cell homeostasis by limiting IL-4 signals. J Exp Med. 2013; 210(7): 1419– 1431. 23797092 PMC3698519
  26. [27]Ramalingam TR, Pesce JT, Sheikh F, Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol. 2008; 9(1): 25– 33. 18066066 PMC2692551
  27. [28]LaPorte SL, Juo ZS, Vaclavikova J, Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008; 132(2): 259– 272. 18243101 PMC2265076
  28. [29]Tanaka Y, Hamano S, Gotoh K, T helper type 2 differentiation and intracellular trafficking of the interleukin 4 receptor-alpha subunit controlled by the Rac activator Dock2. Nat Immunol. 2007; 8(10): 1067– 1075. 17767160
  29. [30]Balic A, Harcus YM, Taylor MD, Brombacher F, Maizels RM. IL-4R signaling is required to induce IL-10 for the establishment of T(h)2 dominance. Int Immunol. 2006; 18(10): 1421– 1431. 16940042
  30. [31]Ahn JS, Agrawal B. IL-4 is more effective than IL-13 for in vitro differentiation of dendritic cells from peripheral blood mononuclear cells. Int Immunol. 2005; 17(10): 1337– 1346. 16141241
  31. [32]Hurdayal R, Nieuwenhuizen NE, Revaz-Breton M, Deletion of IL-4 receptor alpha on dendritic cells renders BALB/c mice hypersusceptible to Leishmania major infection. PLoS Pathog. 2013; 9(10): e1003699. 24204259 PMC3812013
  32. [33]Noval Rivas M, Burton OT, Oettgen HC, Chatila T. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol. 2016; 138(3): 801– 811 e809. 27177780 PMC5014699
  33. [34]Smith KA, Loser S, Varyani F, Concerted IL-25R and IL-4Ralpha signaling drive innate type 2 effector immunity for optimal helminth expulsion. Elife. 2018; 7. PMC6173579 30238872
  34. [35]Motomura Y, Morita H, Moro K, Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity. 2014; 40(5): 758– 771. 24837103
  35. [36]Bal SM, Bernink JH, Nagasawa M, IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol. 2016; 17(6): 636– 645. 27111145
  36. [38]Barnig C, Cernadas M, Dutile S, Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med. 2013; 5(174): 174ra126. PMC3823369 23447017
  37. [39]Zhou W, Toki S, Zhang J, Prostaglandin I2 Signaling and Inhibition of Group 2 Innate Lymphoid Cell Responses. Am J Respir Crit Care Med. 2016; 193(1): 31– 42. 26378386 PMC4731613
  38. [40]Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol. 2013; 132(1): 205– 213. 23688412 PMC3704056
  39. [41]von Moltke J, O’Leary CE, Barrett NA, Kanaoka Y, Austen KF, Locksley RM. Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s. J Exp Med. 2017; 214(1): 27– 37. 28011865 PMC5206504
  40. [42]Yamani A, Wu D, Waggoner L, The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions. J Allergy Clin Immunol. 2018; 142(4): 1159– 1172 e1155. 29157947 PMC5957775
  41. [43]Abdel Aziz N, Nono JK, Mpotje T, Brombacher F. The Foxp3+ regulatory T-cell population requires IL-4Ralpha signaling to control inflammation during helminth infections. PLoS Biol. 2018; 16(10): e2005850. 30379806 PMC6231676
  42. [44]Noval Rivas M, Burton OT, Wise P, Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy. Immunity. 2015; 42(3): 512– 523. 25769611 PMC4366316
  43. [45]Burton OT, Noval Rivas M, Zhou JS, Immunoglobulin E signal inhibition during allergen ingestion leads to reversal of established food allergy and induction of regulatory T cells. Immunity. 2014; 41(1): 141– 151. 25017467 PMC4123130
  44. [46]Abdel-Gadir A, Schneider L, Casini A, Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018; 48(7): 825– 836. 29700872 PMC6021220
  45. [47]Pelly VS, Coomes SM, Kannan Y, Interleukin 4 promotes the development of ex-Foxp3 Th2 cells during immunity to intestinal helminths. J Exp Med. 2017; 214(6): 1809– 1826. 28507062 PMC5460998
  46. [48]Wu X, Di Rienzo A, Ober C. A population genetics study of single nucleotide polymorphisms in the interleukin 4 receptor alpha (IL4RA) gene. Genes Immun. 2001; 2(3): 128– 134. 11426321
  47. [49]Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 1997; 337(24): 1720– 1725. 9392697
  48. [50]Rosa-Rosa L, Zimmermann N, Bernstein JA, Rothenberg ME, Khurana Hershey GK. The R576 IL-4 receptor alpha allele correlates with asthma severity. J Allergy Clin Immunol. 1999; 104(5): 1008– 1014. 10550746
  49. [51]Ober C, Leavitt SA, Tsalenko A, Variation in the interleukin 4-receptor alpha gene confers susceptibility to asthma and atopy in ethnically diverse populations. Am J Hum Genet. 2000; 66(2): 517– 526. 10677312 PMC1288105
  50. [52]Noval Rivas M, Chatila TA. Regulatory T cells in allergic diseases. J Allergy Clin Immunol. 2016; 138(3): 639– 652. 27596705 PMC5023156
  51. [53]Massoud AH, Charbonnier LM, Lopez D, Pellegrini M, Phipatanakul W, Chatila TA. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. Nat Med. 2016; 22(9): 1013– 1022. 27479084 PMC5014738
  52. [54]Del Rosso JQ. MONOCLONAL ANTIBODY THERAPIES for Atopic Dermatitis: Where Are We Now in the Spectrum of Disease Management? J Clin Aesthet Dermatol. 2019; 12(2): 39– 41. PMC6415707 30881583
  53. [55]Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019: 1– 11. PMC6773424 30785362
  54. [58]Lai SY, Xu W, Gaffen SL, The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes. Proc Natl Acad Sci U S A. 1996; 93(1): 231– 235. 8552611 PMC40212
  55. [59]Murata T, Taguchi J, Puri RK. Interleukin-13 receptor alpha’ but not alpha chain: a functional component of interleukin-4 receptors. Blood. 1998; 91(10): 3884– 3891. 9573026
  56. [60]Zhang JL, Simeonowa I, Wang Y, Sebald W. The high-affinity interaction of human IL-4 and the receptor alpha chain is constituted by two independent binding clusters. J Mol Biol. 2002; 315(3): 399– 407. 11786020
  57. [61]Guttman-Yassky E, Bissonnette R, Ungar B, Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019; 143(1): 155– 172. 30194992
  58. [62]Sanchez-Borges M, Capriles-Hulett A, Ortega-Martell JA, Zubeldia IA. New and Potential Treatments for Atopic Dermatitis: Biologicals and Small Molecules. Curr Allergy Asthma Rep. 2019; 19(3): 18. 30815760
  59. [64]Blauvelt A, de Bruin-Weller M, Gooderham M, Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10086): 2287– 2303. 28478972
  60. [65]de Bruin-Weller M, Thaci D, Smith CH, Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018; 178(5): 1083– 1101. 29193016
  61. [66]Hamilton JD, Suarez-Farinas M, Dhingra N, Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014; 134(6): 1293– 1300. 25482871
  62. [67]Wollenberg A, Barbarot S, Bieber T, Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018; 32(6): 850– 878. 29878606
  63. [68]Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015; 7(10): 1043– 1058. 26598956
  64. [70]Faiz S, Giovannelli J, Podevin C, Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019. 30825533
  65. [71]Ivert LU, Wahlgren CF, Ivert L, Lundqvist M, Bradley M. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis. Acta Derm Venereol. 2019; 99(4): 375– 378. 30653240
  66. [72]Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. Int Immunopharmacol. 2018; 54: 303– 310. 29182975
  67. [73]Thomson J, Wernham AGH, Williams HC. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. Br J Dermatol. 2018; 178(4): 897– 902. 29315479
  68. [74]Wollenberg A, Beck LA, Blauvelt A, Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). The British journal of dermatology. 2019. PMC7317598 31407311
  69. [75]Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 2019; 68(2): 158– 166. 30792118
  70. [76]Castro M, Corren J, Pavord ID, Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378(26): 2486– 2496. 29782217
  71. [77]Rabe KF, Nair P, Brusselle G, Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018; 378(26): 2475– 2485. 29782224
  72. [81]Menzella F, Montanari G, Patricelli G, A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag. 2019; 15: 869– 875. 31371974 PMC6636310
  73. [82]Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol. 2015; 136(6): 1431– 1440. 26654192
  74. [83]Schneider JS. Subcutaneous Dupilumab and Mometasone Furoate Nasal Spray for Chronic Rhinosinusitis With Polyps. JAMA Otolaryngol Head Neck Surg. 2016; 142(7): 698– 699. 27258602
  75. [84]Jonstam K, Swanson BN, Mannent LP, Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019; 74(4): 743– 752. 30488542 PMC6590149
  76. [85]Bachert C, Hellings PW, Mullol J, Dupilumab improves patient reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019. 30928658
  77. [86]Ackermann JA, Hofheinz K, Zaiss MM, Kronke G. The double-edged role of 12/15-lipoxygenase during inflammation and immunity. Biochim Biophys Acta Mol Cell Biol Lipids. 2017; 1862(4): 371– 381. 27480217
  78. [87]Gundra UM, Girgis NM, Ruckerl D, Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct. Blood. 2014; 123(20): e110– 122. 24695852 PMC4023427
  79. [88]Kristjansson RP, Benonisdottir S, Davidsson OB, A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. Nat Genet. 2019; 51(2): 267– 276. 30643255
  80. [89]Ruffner MA, Kennedy K, Cianferoni A. Pathophysiology of eosinophilic esophagitis: recent advances and their clinical implications. Expert Rev Clin Immunol. 2018: 1– 13. PMC9044497 30394139
  81. [90]Durrani S, Rothenberg M. Recent advances in eosinophilic esophagitis. F1000Res 2017; 6: 1775. 29043074 PMC5621107
  82. [91]Davis BP, Stucke EM, Khorki ME, Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment. JCI Insight. 2016; 1(4): e86355. 27158675 PMC4855700
  83. [92]REGENERON AND SANOFI ANNOUNCE POSITIVE PHASE 2 STUDY RESULTS FOR DUPILUMAB IN PATIENTS WITH ACTIVE MODERATE-TO-SEVERE EOSINOPHILIC ESOPHAGITIS [press release]. 2017.
  84. [93]Sastre J, Davila I. Dupilumab: A New Paradigm for the Treatment of Allergic Diseases. J Investig Allergol Clin Immunol. 2018; 28(3): 139– 150. 29939132
  85. [94]Albuhairi S, Rachid R. The Emerging Biologic Therapies on Food Allergy. Ann Allergy Asthma Immunol. 2019. 30928415
  86. [95]Rial MJ, Barroso B, Sastre J. Dupilumab for treatment of food allergy. J Allergy Clin Immunol Pract. 2019; 7(2): 673– 674. 30075339

Cited by

Sorted by citations

Authors
Harb, H., & Chatila, T. A.
Affiliations
Boston Children's Hospital (US)
Corresponding author
Chatila, Talal A.
ORCID
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2019-09-30
Volume
50
Issue
1
Pages
5-14
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
DOI
10.1111/cea.13491
PMC
PMC6930967
OpenAlex
W2973122049
Cited by
518
References
4
Citations by year
2026: 77 · 2025: 102 · 2024: 98 · 2023: 102 · 2022: 80 · 2021: 36 · 2020: 22
FWCI
6.70
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Clinical & Experimental Allergy (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (1R01AI1269151, 5R01AI065617)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
Keywords
dupilumab, IL-4 receptor alpha, IL-4, IL-13, Th2 cytokines, allergic diseases, monoclonal antibodies, receptor signalling pathways, precision medicine, allergic rhinitis, atopic dermatitis, asthma
MeSH terms
Anaphylaxis, Asthma, Chronic Disease, Dermatitis, Atopic, Food Hypersensitivity, Humans, Inflammation, Nasal Polyps, Sinusitis, Interleukin-4, Th2 Cells, Interleukin-13, Anti-Allergic Agents, T-Lymphocytes, Regulatory, STAT6 Transcription Factor, Interleukin-4 Receptor alpha Subunit, Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized, Rhinitis, Allergic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review